Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $57.48, for a total value of $9,556,050.00. Following the sale, the chief executive officer directly owned 8,775,283 shares in the company, valued at $504,403,266.84. This represents a 1.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM stock opened at $60.27 on Friday. The stock has a market cap of $10.82 billion, a price-to-earnings ratio of -35.04 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The business has a 50 day moving average price of $50.38 and a 200 day moving average price of $54.52.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same period in the prior year, the company earned ($0.24) earnings per share. The company’s revenue was up 36.1% compared to the same quarter last year. Equities research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on TEM. Jefferies Financial Group started coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Guggenheim decreased their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Finally, HC Wainwright decreased their price target on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $68.54.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after buying an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Tempus AI in the 1st quarter valued at $116,000. Prudential Financial Inc. purchased a new position in shares of Tempus AI in the second quarter worth approximately $276,000. Russell Investments Group Ltd. raised its stake in Tempus AI by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after purchasing an additional 1,146 shares during the period. Finally, Invesco Ltd. lifted its stake in Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after acquiring an additional 204,629 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.